Imidazolidinones as NS3-serine protease inhibitors of hepatitis C virus
US6838475B2 · kind B2 · utility
42Cited by
1References
43Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 19, 2001 |
| Grant date | Jan 4, 2005 |
| Priority date | — |
| Expiry date | Jul 28, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention discloses novel imidazolidinones which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazolidinones as well as methods of using them to treat disorders associated with the HCV protease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.